Company intelligence / Profile preview

Hefei Afana Biotechnology

Ownership: Private
Development stage: Other

Overview

Afana Biotechnology is a Chinese biopharmaceutical company focused on the development of mRNA-based therapeutics and vaccines. Founded in 2021 and headquartered in Hefei, the company utilizes its proprietary mRNA sequence design and lipid nanoparticle (LNP) delivery platforms to target infectious diseases and oncology. Its lead candidate, AFN01, is an mRNA vaccine for COVID-19 that has entered clinical trials. The company's pipeline also includes programs for rabies, shingles, and personalized cancer vaccines. Afana aims to build a comprehensive mRNA drug development ecosystem, encompassing R&D, pilot production, and large-scale manufacturing.

Therapeutic areas: OncologyInfectious Diseases
Modalities: mRNA-based drugsLipid nanoparticle delivery therapyVaccine
Industry: Biotech

Drug pipeline

3 assets

AFN0328

2 more assets in the full pipeline.

Beyond the preview

Go deeper on Hefei Afana Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hefei Afana Biotechnology.